The global anti-infectiveagents market is expected to
reach over USD 111.4 billion by 2024 according to a new report by Grand View
Research, Inc. The rising prevalence of infectious diseases such as HIV, H1N1,
and Ebola virus reflect the profound changes in behavioral patterns of
communities over the recent decades. The societal changes and the increasing
awareness levels amongst the healthcare professionals and the patients
pertaining to these diseases are driving the anti-infective agents market.
Organizations,
such as the WHO and CDC are actively involved in spreading awareness amongst
people regarding the implications of infectious diseases, which are fatal in
nature and the importance of early treatment. The CDC has collaborated with the
National Health Ministry (NHM) in an attempt to spread awareness and enhance
the treatment rates for communicable diseases in developing countries such as
Brazil, China, Nigeria, and India.
However, the
introduction of novel therapeutics with increased potency and efficacy and the
commercialization of pipeline products, such as commercialization of
Omadacycline in 2018 for the treatment of Community Acquired Bacterial
Pneumonia (CABP) in the near future, are expected to favorthe market growth.
Full research report on anti-infective agents market
analysis: http://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market
Further keyfindings from the study suggest:
·
The antibacterial segment was observed to
account for the largest share of over 54.0% in 2015. The large market share is
attributed to the fact that antibacterials are preferred as the first line of
treatment for a large range of infections, the high prescription rates
exhibited by this segment, and the increased accessibility of the
antibacterials due to their over-the-counter status.
·
The development of combination drugs to
treat and prevent, serious and life-threatening infections is expected to
accentuate the usage of anti-infective drugs. For instance, in
2012, Gilead Sciences, Inc. launched Stribild, which is a comprehensive
treatment regimen inclusive of four drugs(cobicistat, elvitegravir,
emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV
patients without prior retroviral treatment record.
·
The anti-viral agents segment is expected
to grow at a swift CAGR of over 3.5% owing to the high price associated with
the introduction of new potent anti-viral drugs such as Vicriviroc for HIV
treatment purpose
·
North America dominated the overall
anti-infective agents market in terms of revenue of over25.0 billion in
2015.The rise in prevalence of infectious diseases including hospital-acquired
infections in both, children and adults, and the resultant overuse of
antibiotics coupled with the increased accessibility to non-prescription
anti-infectives in the market are the factors responsible for its
dominance.
·
Asia Pacific is one of the fastest growing
regional segments owing to the presence of high, unmet market demand for novel
drugs, rapid improvements in healthcare infrastructure coupled with the rising
awareness amongst healthcare professionals as well as patients
·
Some of the major companies operating in
this market are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers
Squibb Co., Merck & Co., Inc, Bayer Healthcare AG, AstraZeneca Plc,
Boehringer Ingelheim, and Novartis AG.
·
Effective disease management involves a
range of long-term strategies such as new product development, merger and
acquisitions, co-development, and expansion. For instance, in 2015, ReViral has
received a funding of USD 21 million for the development of its RV521 drug by
the Wellcome Trust.
View more reports of this category by Grand
View Research at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
anti-infective agents market on the basis of type and region:
Anti-infective
agents market type outlook, by revenue (USD Million, 2014 - 2024)
·
Antibacterial
o
Cephalosporins
o
Penicillins
o
Fluoroquinolones
o
Macrolides
o
Carbapenems
o
Others
·
Antifungal
o
Azoles
o
Echinocandins
o
Polyenes
·
Antiviral
Anti-infective
agents market regional outlook, by revenue (USD Million, 2014 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
o
France
·
Asia Pacific
o
Japan
o
India
o
China
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
Access
press release by Grand View Research: https://www.grandviewresearch.com/press-release/global-anti-infective-agents-market
About
Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
